Web site reference to full labeling does not create balance; FDA challenges Abelcet home page.
THE LIPOSOME COMPANY ABELCET HOME PAGE LINK TO LABELING NOT "SUFFICIENT" to provide fair balance, FDA's Division of Drug Marketing, Advertising & Communications told the company in a Dec. 11 letter. "DDMAC does not consider the mere inclusion of a reference to a product's full prescribing information as being sufficient to balance any claims being made," the letter states. The Abelcet home page (www.lipo.com) includes an Internet link to full prescribing information. Abelcet is amphatericin B lipid complex indicated against invasive fungal infections.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth